Showing 8761-8770 of 19239 results for "".
- Machine Learning Can Predict Eyes at Risk for Diabetic Retinopathy Progressionhttps://reachmd.com/news/machine-learning-can-predict-eyes-at-risk-for-diabetic-retinopathy-progression/2457233/by Lori Solomon Automated machine learning models may help identify eyes
- Therapeutic Plasma Exchange and Biological Aging: A New Hope in Geriatricshttps://reachmd.com/news/therapeutic-plasma-exchange-and-biological-aging-a-new-hope-in-geriatrics/2474990/Clinicians have long sought interventions capable of reversing biological aging and improving patient resilience, and now a
- GLP-1 Receptor Agonists: Bridging Metabolic Control and Cardiovascular Protectionhttps://reachmd.com/news/glp-1-receptor-agonists-bridging-metabolic-control-and-cardiovascular-protection/2475771/The expanding use of GLP-1 receptor agonists such as Ozempic is challenging the traditional divide between metabolic control and cardiovascular protection, unveiling underrecognized potential for stroke prevention in patients with type 2 diabetes. The utilization of
- Weight Loss and Glucose Management: Transitioning from Old to New Medicationshttps://reachmd.com/news/weight-loss-and-glucose-management-transitioning-from-old-to-new-medications/2474175/Emerging research affirms that next-generation weight loss and glucose management medications are transforming treatment outcomes for patients with type 2 diabetes, offering superior efficacy and potential economic savings. The advent of these c
- Barriers To SGLT2 Inhibitor Access In Heart Failure Care In Jordanhttps://reachmd.com/news/barriers-to-sglt2-inhibitor-access-in-heart-failure-care-in-jordan/2486587/Key Takeaways: Low initiation and low reported approval for heart failure without diabetes were observed despite generally favorable physician knowledge and attitudes toward SGLT2 inhibitors. Misclassification of SGLT2 inhibitors as diabetes-only medic
- Bridging ADHD and Metabolic Disorders: Clinical Implications of Shared Pathwayshttps://reachmd.com/news/bridging-adhd-and-metabolic-disorders-clinical-implications-of-shared-pathways/2474583/Exploring the critical connection between ADHD and metabolic disorders reveals insights into dopamine gene modifications, challenges in glycemic regulation, and the effects of maternal diabetes on children. Insights from Diabetes and Endocrinolo
- Advancing Detection: Maternal A1c as a Diagnostic Tool in Early GDM Identificationhttps://reachmd.com/news/advancing-detection-maternal-a1c-as-a-diagnostic-tool-in-early-gdm-identification/2473840/The pursuit of earlier, more effective screening strategies for gestational diabetes mellitus (GDM) has led to growing interest in a nontraditional yet accessible biomarker: maternal hemoglobin A1c (HbA1c). While traditionally reserved for diabetes monitoring outsi
- Op-Ed: Confessions of a 31 Year-Old Doctor with 1 Million in Debthttps://reachmd.com/news/op-ed-confessions-of-a-31-year-old-doctor-with-1-million-in-debt/2457401/To understand how I accrued $1 million in debt, you must first understand where I come from.
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://reachmd.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://reachmd.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm